Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hypercoagulation Screening as Innovative Tool for Risk Assessment, Early Diagnosis and Prognosis in Cancer

NCT02622815 is registered in ClinicalTrials.gov with A.O. Ospedale Papa Giovanni XXIII as lead sponsor.

NCT NCT02622815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02622815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hypercoagulation Screening as Innovative Tool for Risk Assessment, Early Diagnosis and Prognosis in Cancer
Lead sponsor
A.O. Ospedale Papa Giovanni XXIII
Phase
Observational
Overall status
Unknown status
Start date
April 30, 2012
Completion date
January 31, 2020
Enrollment
16,000 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cancer patients, healthy blood donors, moli-sani subjects